Related references
Note: Only part of the references are listed.Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Ramaswamy Govindan et al.
CLINICAL LUNG CANCER (2022)
The regulatory role of autophagy-related miRNAs in lung cancer drug resistance
Mahshid Shahverdi et al.
BIOMEDICINE & PHARMACOTHERAPY (2022)
Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments
Luke A. McGuinness et al.
RESEARCH SYNTHESIS METHODS (2021)
Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials
Jiatao Hao et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)
Evaluation of efficacy and safety of PARP inhibitors in breast cancer: A systematic review and meta-analysis
Xiao-Fei Chang et al.
BREAST (2021)
Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study
Suresh S. Ramalingam et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non-small-cell Lung Cancer: SWOG 1206 (8811)
Athanassios Argiris et al.
CLINICAL LUNG CANCER (2021)
PARP Inhibitors in Small-Cell Lung Cancer: Rational Combinations to Improve Responses
Erik H. Knelson et al.
CANCERS (2021)
Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naive Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study
Lauren Averett Byers et al.
CLINICAL CANCER RESEARCH (2021)
Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis
Francesco Schettini et al.
EUROPEAN JOURNAL OF CANCER (2021)
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer
David E. Kozono et al.
LUNG CANCER (2021)
Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation study
Jeffrey M. Clarke et al.
LUNG CANCER (2021)
Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer
Julia Judd et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Mulicentar Phase II Trial
Alice P. Chen et al.
JCO PRECISION ONCOLOGY (2021)
PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review
Raffaele Ratta et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2020)
The Therapeutic Potential of DNA Damage Repair Pathways and Genomic Stability in Lung Cancer
Joshua T. Burgess et al.
FRONTIERS IN ONCOLOGY (2020)
Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial
Laurie E. Steffen McLouth et al.
CANCER MEDICINE (2020)
Comparison of Poly (ADP-ribose) Polymerase Inhibitors (PARPis) as Maintenance Therapy for Platinum-Sensitive Ovarian Cancer: Systematic Review and Network Meta-Analysis
Amos Stemmer et al.
CANCERS (2020)
PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
Maddison Rose et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
Evolving insights: how DNA repair pathways impact cancer evolution
Jiadong Zhou et al.
CANCER BIOLOGY & MEDICINE (2020)
PARP inhibitors for small cell lung cancer and their potential for integration into current treatment approaches
Ranya Barayan et al.
JOURNAL OF THORACIC DISEASE (2020)
PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
Patrick G. Pilie et al.
CLINICAL CANCER RESEARCH (2019)
RoB 2: a revised tool for assessing risk of bias in randomised trials
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies
Leonard J. Appleman et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors
Florence Atrafi et al.
CLINICAL CANCER RESEARCH (2019)
Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study
Taofeek K. Owonikoko et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy
Zuan-Fu Lim et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
M. Catherine Pietanza et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung Cancer
Suresh S. Ramalingam et al.
CLINICAL CANCER RESEARCH (2017)
Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer
Martin Reck et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Phase I study of veliparib in combination with gemcitabine
Ronald Stoller et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysis
Zhengqiang Bao et al.
ONCOTARGET (2016)
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors
Patricia M. LoRusso et al.
CLINICAL CANCER RESEARCH (2016)
Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair
Miguel A. Villalona-Calero et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
Yves Pommier et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair
Miguel A. Villalona-Calero et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
DNA damage and the balance between survival and death in cancer biology
Wynand P. Roos et al.
NATURE REVIEWS CANCER (2016)
A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC)
Hidenori Mizugaki et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study
Minesh P. Mehta et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511)
Taofeek K. Owonikoko et al.
LUNG CANCER (2015)
Targeting the DNA Damage Response in Cancer
Mark J. O'Connor
MOLECULAR CELL (2015)
Lung Cancer: Epidemiology, Etiology, and Prevention
Charles S. Dela Cruz et al.
CLINICS IN CHEST MEDICINE (2011)
Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies
Shivaani Kummar et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Twenty-Seven Years of Phase III Trials for Patients with Extensive Disease Small-Cell Lung Cancer: Disappointing Results
Isao Oze et al.
PLOS ONE (2009)
ABT-888, an orallyactive poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models
Cherrie K. Donawho et al.
CLINICAL CANCER RESEARCH (2007)
Poly(ADP-ribose) polymerase (PARP-1) is not involved in DNA double-strand break recovery -: art. no. 7
G Noël et al.
BMC CELL BIOLOGY (2003)
Share Paper
